Disease

Endometrial Cancer

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 11, 2026 · PHASE EARLY PHASE 1 TRIAL

Tirzepatide in Obesity-Driven Endometrial Cancer

ClinicalTrials.gov

This is an early-phase, uncontrolled window-of-opportunity study with a planned sample of 20 patients examining a mechanistic hypothesis in a pre-operative setting; no results are yet reported.

PreliminaryObesity Tirzepatide NCT07065552

Reported

Planned enrollment20

Study phaseEARLY_PHASE1

Primary outcome measureChange in Proliferation, Baseline – Up to 6…

SEP 10, 2026 · PHASE 1 TRIAL

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

ClinicalTrials.gov

This is a Phase 1 open-label trial still recruiting, with no results posted; it represents early-stage evaluation of a novel therapeutic agent.

PreliminarySystImmune NCT06293898 BL-M07D1

Reported

PhasePHASE 1

Planned enrollment280

Study durationapproximately 24 months

JUL 24, 2026 · JOURNAL ARTICLE

Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.

Journal of Obstetrics and Gynaecology

Small prospective observational study comparing three weight-management approaches in endometrial cancer patients, with no randomization and limited sample size limiting causal inference.

PreliminaryHui Zeng Yuxuan Wei Zhaohui Zhong

Reported

Sample size53

Sleeve gastrectomy arm10

Semaglutide arm23